Max Rosett
Director of Finance/CFO at IMMUNOME, INC.
Net worth: 283 147 $ as of 29/04/2024
Max Rosett active positions
| Companies | Position | Start | End |
|---|---|---|---|
| IMMUNOME, INC. | Comptroller/Controller/Auditor | 09/05/2024 | - |
| Chief Operating Officer | 01/10/2023 | - | |
| Director of Finance/CFO | 01/01/2024 | - | |
| Investor Relations Contact | 01/10/2023 | - |
Career history of Max Rosett
Former positions of Max Rosett
| Companies | Position | Start | End |
|---|---|---|---|
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Corporate Officer/Principal | - | 31/10/2023 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Chief Operating Officer | 28/02/2022 | 30/09/2023 |
| Corporate Officer/Principal | 31/12/2021 | 28/02/2022 |
Training of Max Rosett
| Yale University | Undergraduate Degree |
| Georgia Institute of Technology | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Private companies | 2 |
|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Finance |
- Stock Market
- Insiders
- Max Rosett
- Experience
